

**To:** [redacted]@univr.it; [redacted]@univr.it  
**Cc:** [redacted]@sciensano.be; [redacted]@umcutrecht.nl; [redacted]@teamitresearch.com; [redacted]@teamitresearch.com; [redacted]@idiapjgol.org; [redacted]@idiapjgol.org; [redacted]@idiapjgol.info; [redacted]@idiapjgol.info; [redacted]@child.pedi.unipd.it; [redacted]@child.pedi.unipd.it; [redacted]@clin.au.dk; [redacted]@clin.au.dk; [redacted]@u-bordeaux.fr; [redacted]@u-bordeaux.fr; [redacted]@u-bordeaux.fr; [redacted]@u-bordeaux.fr; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@leibniz-bips.de; [redacted]@leibniz-bips.de; [redacted]@leibniz-bips.de; [redacted]@leibniz-bips.de; [redacted]@ars.toscana.it; [redacted]@ars.toscana.it; [redacted]@ars.toscana.it; [redacted]@ars.toscana.it; [redacted]@sciensano.be; [redacted]@sciensano.be; [redacted]@lareb.nl; [redacted]@lareb.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@lareb.nl; [redacted]@rti.org; [redacted]@rti.org; [redacted]@rti.org; [redacted]@rti.org; [redacted]@farmasi.uio.no; [redacted]@deplazio.it; [redacted]@deplazio.it; [redacted]@deplazio.it; [redacted]@deplazio.it; [redacted]@univr.it; [redacted]@pentafoundation.org; [redacted]@pentafoundation.org; [redacted]@pharmo.nl; [redacted]@pharmo.nl; [redacted]@pharmo.nl; [redacted]@pharmo.nl; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@simg.it; [redacted]@simg.it; [redacted]@umcutrecht.nl; [redacted]@umcutrecht.nl; [redacted]@dsru.org; [redacted]@dsru.org; [redacted]@dsru.org; [redacted]@dsru.org

**From:** [redacted]  
**Sent:** Thur 3/25/2021 6:47:27 AM  
**Subject:** RE: Very rare cases of haemorrhage with immune thrombocytopenia, not higher incidence of blood clots is the likely issue with Covid-19 vaccines  
**Received:** Thur 3/25/2021 6:48:35 AM  
[GTH Stellungnahme AstraZeneca 3 22 2021.pdf](#)

Hi [redacted]

[redacted] shared this guide (unfortunately only in German).

Best wishes,

[redacted]

**From:** [redacted] <[redacted]@lareb.nl>

**Sent:** Wednesday, March 24, 2021 4:39 PM

**To:** [redacted]@univr.it; [redacted] <[redacted]@dsru.org>; [redacted]

<[redacted]@umcutrecht.nl>

**Cc:** [redacted] <[redacted]@sciensano.be>; [redacted] <[redacted]@umcutrecht.nl>; [redacted]@teamitresearch.com; [redacted]@idiapjgol.org; [redacted]@idiapjgol.info; [redacted]@child.pedi.unipd.it; [redacted]@clin.au.dk; [redacted]@clin.au.dk; [redacted]@clin.au.dk; [redacted]@u-bordeaux.fr; [redacted]@u-bordeaux.fr; [redacted]@gmail.com; [redacted]@gmail.com; [redacted]@leibniz-bips.de; [redacted]@leibniz-bips.de; [redacted]@ars.toscana.it; [redacted]@ars.toscana.it; [redacted] <[redacted]@sciensano.be>; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted] <[redacted]@lareb.nl>; [redacted]@rti.org; [redacted]@rti.org; [redacted] <[redacted]@farmasi.uio.no>; [redacted]@deplazio.it; [redacted]@deplazio.it; [redacted] <[redacted]@univr.it>; [redacted]@pentafoundation.org; [redacted]@pharmo.nl; [redacted] <[redacted]@pharmo.nl>; [redacted]@gmail.com; [redacted] <[redacted]@simg.it>; [redacted] <[redacted]@simg.it>; [redacted]@dsru.org; [redacted] <[redacted]@dsru.org>

**Subject:** RE: Very rare cases of haemorrhage with immune thrombocytopenia, not higher incidence of blood clots is the likely issue with Covid-19 vaccines

**OBS!** Mailen er fra en ekstern afsender. Vær opmærksom på links og vedhæftede filer. **NB!** This email is from an external sender. Be aware of links and attachments.

Hi [redacted]

In the Netherlands the treatment guidelines used by the Dutch Association of Internal Medicine are based on the German treatment guidelines, the Germans also have a English translation of this document, please see

[https://gth-online.org/wp-content/uploads/2021/03/GTH Stellungnahme AstraZeneca engl. 3 24 2021.pdf](https://gth-online.org/wp-content/uploads/2021/03/GTH_Stellungnahme_AstraZeneca_engl.3_24_2021.pdf)

Maybe this can help!

Kind regards,

[redacted]



3 - 7

Dubbel